首页 > 市场调查报告书 > 医疗设备

生技设备

市场调查报告书

商品编码

1535578

生物光子市场 - 按技术（体外、体内）、按应用（透视成像、显微镜、内部成像、光谱分子、分析感测、光疗法、表面成像、生物感测器）、按最终用途和预测，2024 年- 2032

Biophotonics Market - By Technology (In-vitro, In-vivo), By Application (See-through Imaging, Microscopy, Inside Imaging, Spectro Molecular, Analytics Sensing, Light Therapy, Surface Imaging, Biosensors), By End Use & Forecast, 2024 - 2032

出版日期: 2024年06月04日 | 出版商:

Global Market Insights Inc. | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于对非侵入性诊断的需求不断增加和医疗保健支出不断增加，2024年至2032年全球生物光子市场规模的复合年增长率将达到10.9%。非侵入性诊断方法，例如先进的影像和光疗法，为患者和提供者提供侵入性较小的选择，恢復时间更快，舒适度更高。此外，不断增长的医疗保健预算使得对尖端技术和创新解决方案的投资成为可能。对非侵入性技术的需求增加和医疗进步的财政资源增加相结合，促进了生物光子产业的大幅成长，支持其扩张和发展。

例如，2024 年 3 月，BioPhotas, Inc. 推出了 Celluma CONTOUR，这是一款经 FDA 批准的光治疗设备，用于身体轮廓、皮肤老化和疼痛管理，标誌着光治疗的重大进步。 FDA 对该设备的批准突显了生物光子学应用的监管支持和验证不断增加。这项进展反映了将光疗法融入主流医疗实践的更广泛趋势，可能推动市场扩张并鼓励对生物光子技术的进一步投资和研究。

生物光子市场根据技术、应用、最终用途和地区进行划分。

由于医疗诊断领域在提高诊断准确性和效率方面发挥着至关重要的作用，因此到 2032 年，医疗诊断领域将显着扩张。光学成像和萤光技术等生物光子技术的进步显着改善了疾病检测和监测。对早期精确诊断工具不断增长的需求推动了采用，因为这些技术提供了非侵入性和高度敏感的解决方案。此外，增加对创新诊断应用的研发投资进一步巩固了该领域在生物光子产业的主导地位。

到 2032 年，光疗领域将获得可观的收益，这归因于其在治疗一系列医疗状况和改善患者治疗效果方面的应用不断增长。光疗技术的进步为疼痛管理、皮肤病和情绪障碍提供了非侵入性、有效的解决方案。人们越来越认识到光治疗的好处，加上对替代和补充疗法的需求不断增长，推动了这一领域的大幅成长。治疗应用范围的扩大和技术创新进一步巩固了其在市场上的地位。

在其强大的医疗基础设施、先进的研究能力和对医疗创新的高度重视的推动下，欧洲生物光子市场份额将在 2024 年和 2032 年达到显着的复合年增长率。该地区对生物光子学研究和开发的广泛投资，加上政府的支持性政策以及对先进诊断和治疗解决方案不断增长的需求，推动了市场的显着增长。欧洲已建立的领先学术和研究机构网络，以及积极整合尖端技术的方法，使其成为生物光子产业的显着贡献者。

产业生态系统分析
供应商矩阵
利润率分析
技术与创新格局
专利分析
重要新闻和倡议
监管环境
衝击力
- 成长动力
  - 技术进步
  - 对非侵入性诊断技术的需求不断增长
  - 增加生命科学领域的应用
  - 政府措施和资金
  - 个人化医疗需求不断成长
- 产业陷阱与挑战
  - 技术成本高
  - 复杂的监管环境
成长潜力分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：依技术分类，2021 - 2032 年

体外
体内

第 6 章：市场估计与预测：依应用分类，2021 - 2032

透视成像
显微镜检查
内部影像
光谱分子
分析感测
光疗
表面成像
生物感测器

第 7 章：市场估计与预测：依最终用途，2021 - 2032 年

测试和组件
医学治疗
医疗诊断
非医疗应用

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 英国
- 德国
- 法国
- 义大利
- 西班牙
- 欧洲其他地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 澳新银行
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
MEA
- 阿联酋
- 南非
- 沙乌地阿拉伯
- MEA 的其余部分

第 9 章：公司简介

Affymetrix Inc. (Thermo Fisher Scientific Inc.)
Becton, Dickinson and Company
Carl Zeiss AG
Glenbrook Technologies
Hamamatsu Photonics K.K
IDEX
IPG Photonics Corporation
NU Skin Enterprises
Olympus Corporation
Oxford Instruments PLC
PerkinElmer Inc.
Thermo Fisher Scientific
TOSHIBA CORPORATION
Zecotek Photonics Inc.
ZEISS Group
Zenalux Biomedical Inc.

简介目录

Product Code: 9733

Global Biophotonics Market size will register a 10.9% CAGR from 2024 to 2032, owing to the increasing demand for non-invasive diagnostics and rising healthcare spending. Non-invasive diagnostic methods, such as advanced imaging and light-based therapies, offer patients and providers less intrusive options with faster recovery times and improved comfort. Also, growing healthcare budgets enable investment in cutting-edge technologies and innovative solutions. This combination of heightened demand for non-invasive techniques and increased financial resources for medical advancements fosters substantial growth in the biophotonics industry, supporting its expansion and development.

For instance, in March 2024, BioPhotas, Inc. introduced the Celluma CONTOUR, an FDA-cleared light therapy device for body contouring, aging skin, and pain management, marking a significant advancement in light-based treatments. The FDA clearance of this device underscores the increasing regulatory support and validation for biophotonics applications. This advancement reflects a broader trend of integrating light therapy into mainstream medical practices, potentially driving market expansion and encouraging further investment and research in biophotonics technologies.

The biophotonics market is divided based on technology, application, end-use, and region.

The medical diagnostics segment will witness remarkable expansion through 2032 due to its crucial role in enhancing diagnostic accuracy and efficiency. Advances in biophotonics technologies, such as optical imaging and fluorescence-based techniques, significantly improve disease detection and monitoring. The growing demand for early and precise diagnostic tools drives adoption, as these technologies offer non-invasive and highly sensitive solutions. Additionally, increasing investments in research and development for innovative diagnostic applications further bolster the segment's dominance in the biophotonics industry.

The light therapy segment will garner considerable gains by 2032, attributed to its growing application in treating a range of medical conditions and improving patient outcomes. Advances in light therapy technologies offer non-invasive, effective solutions for pain management, skin disorders, and mood disorders. The increasing awareness of the benefits of light-based treatments, coupled with rising demand for alternative and complementary therapies, drives substantial growth in this segment. The expanding range of therapeutic applications and technological innovations further solidify its position in the market.

Europe biophotonics market share will reach a noteworthy CAGR during 2024 and 2032, propelled by its robust healthcare infrastructure, advanced research capabilities, and a strong emphasis on medical innovation. The region's extensive investment in biophotonics research and development, coupled with supportive government policies and a growing demand for advanced diagnostic and therapeutic solutions, drives significant market growth. Europe's established network of leading academic and research institutions, along with its proactive approach to integrating cutting-edge technologies, makes it a notable contributor to the biophotonics industry.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Data sources
- 1.4.1 Primary
- 1.4.2 Secondary
  - 1.4.2.1 Paid sources
  - 1.4.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360º synopsis, 2021 - 2032

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Vendor matrix
3.3 Profit margin analysis
3.4 Technology & innovation landscape
3.5 Patent analysis
3.6 Key news and initiatives
3.7 Regulatory landscape
3.8 Impact forces
- 3.8.1 Growth drivers
  - 3.8.1.1 Advancements in technology
  - 3.8.1.2 Rising demand for non-invasive diagnostic techniques
  - 3.8.1.3 Increasing applications in life sciences
  - 3.8.1.4 Government initiatives and funding
  - 3.8.1.5 Rising demand for personalized medicine
- 3.8.2 Industry pitfalls & challenges
  - 3.8.2.1 High cost of technology
  - 3.8.2.2 Complex regulatory environment
3.9 Growth potential analysis
3.10 Porter's analysis
- 3.10.1 Supplier power
- 3.10.2 Buyer power
- 3.10.3 Threat of new entrants
- 3.10.4 Threat of substitutes
- 3.10.5 Industry rivalry
3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategic outlook matrix

Chapter 5 Market Estimates & Forecast, By Technology, 2021 - 2032 (USD Billion)

5.1 In-vitro
5.2 In-vivo

Chapter 6 Market Estimates & Forecast, By Application, 2021 - 2032 (USD Billion)

6.1 See-through imaging
6.2 Microscopy
6.3 Inside imaging
6.4 Spectro molecular
6.5 Analytics sensing
6.6 Light therapy
6.7 Surface imaging
6.8 Biosensors

Chapter 7 Market Estimates & Forecast, By End Use, 2021 - 2032 (USD Billion)

7.1 Tests and components
7.2 Medical therapeutics
7.3 Medical diagnostics
7.4 Non-medical application

Chapter 8 Market Estimates & Forecast, By Region, 2021 - 2032 (USD Billion)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 UK
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 South Korea
- 8.4.5 ANZ
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 MEA
- 8.6.1 UAE
- 8.6.2 South Africa
- 8.6.3 Saudi Arabia
- 8.6.4 Rest of MEA